autologous blood and marrow transplantation - Blog Science ...

More documents

Recommendations

Info

PREFACE The Ninth International Symposium of Blood and Marrow Transplantation provided an extraordinarily dynamic overview of the field in just over two days. We hope that the sense of enthusiasm, the high level of scientific discourse, and the comprehensiveness of topic coverage evident during the Symposium is conveyed, at least in part, by these Proceedings. During the Symposium, Dr. Hans Kolb was honored as the third recipient of the van Bekkum Stem Cell Award in recognition of his outstanding contributions to the field. We hope that these Proceedings will continue to serve as a guide to the progress we have achieved and to the major advances we have yet to make on behalf of our present and future patients. Karel A. Dicke Arlington Cancer Center Arlington, Texas Armand Keating The Toronto and Princess Margaret Hospitals University of Toronto Toronto, Ontario vii
Page 1: AUTOLOGOUS BLOOD AND MARROW TRANSPL
Page 5 and 6: AUTOLOGOUS BLOOD AND MARROW TRANSPL
Page 7: ACKNOWLEDGMENTS We wish to thank Wi
Page 13 and 14: CHAPTER 1: AML TABLE OF CONTENTS 4H
Page 15 and 16: Table of Contents Autografting for
Page 17 and 18: Table of Contents xv VACOP-B Plus A
Page 19 and 20: Table of Contents xvii High Dose Se
Page 21 and 22: Table of Contents Autologous Blood
Page 23 and 24: Table of Contents Stem Cell Reinfus
Page 25: CHAPTER 15: NEW AVENUES Table of Co
Page 28 and 29: xxvi List of Abbreviations CAV cisp
Page 30 and 31: xxviii List of Abbreviations I IBC
Page 32 and 33: xxx List of Abbreviations PSS progr
Page 35: CHAPTER 1 AML
Page 38 and 39: 4 Chapter 1: AML contribute to rela
Page 40 and 41: 6 Chapter 1: AML Table 1. Purging e
Page 42 and 43: 8 Chapter 1: AML graft. We plan to
Page 44 and 45: 10 Chapter 1: AML years that a sign
Page 46 and 47: 12 Chapter 1: AML Subgroup Risk gro
Page 48 and 49: 14 Chapter 1: AML 2. Zittoun RA, Ma
Page 50 and 51: 16 Chapter I: AML placebo-controlle
Page 52 and 53: 18 Chapter 1: AML 6. Hellstrand K,
Page 54 and 55: 20 Chapter 1: AML apheresis after G
Page 56 and 57: 22 Chapter 1: AML Table 1. Clinical
Page 58 and 59:
24 Chapter 1: AML exhibit low-densi
Page 60 and 61:
26 Chapter 1: AML Disease-Free Surv
Page 62 and 63:
28 Chapter 1: AML Disease-Free Surv
Page 64 and 65:
30 Chapter 1: AML 2 CO Disease-Free
Page 66 and 67:
32 Chapter 1:AML Table 3. Probabili
Page 68 and 69:
34 Chapter 1: AML Eric Martin (Medi
Page 70 and 71:
36 Chapter 1: AML 23. Howell AL, Ba
Page 72 and 73:
Autologous Blood Cell Transplantati
Page 74 and 75:
40 Chapter 1: AML quarter of the pa
Page 76 and 77:
42 Chapter 1: AML of the EBMT. 32 A
Page 78 and 79:
44 Chapter 1: AML 7. O'Donnell MR,
Page 80 and 81:
Immunotherapy With IL-2 After Autol
Page 82 and 83:
48 Chapter 1: AML Several centers h
Page 84 and 85:
50 Chapter 1 : AML occur within the
Page 86 and 87:
52 Chapter 1: AML Information Scien
Page 89:
CHAPTER 2 ALL
Page 92 and 93:
58 Chapter 2: ALL Table 1. Comparis
Page 94 and 95:
60 Chapter 2: ALL UKALL XII). This
Page 96 and 97:
Adult ALL: BMT in First Remission f
Page 98 and 99:
64 Chapter 2: ALL leukemia) appears
Page 100 and 101:
66 Chapter 2: ALL recent update, ho
Page 102 and 103:
68 Chapter 2: ALL in parallel, and
Page 104 and 105:
70 Chapter 2: ALL A, Prentice G, Gl
Page 106 and 107:
Autologous Hematopoietic Stem Cell
Page 108 and 109:
74 Chapter 2: ALL Table 1. Patient
Page 110 and 111:
76 Chapter 2: ALL Table 3. Hematolo
Page 112 and 113:
78 Chapter 2: ALL 1,0 i j CR3 (n= 3
Page 114 and 115:
80 Chapter 2: ALL 20 40 60 < 5 week
Page 116 and 117:
82 Chapter 2: ALL Other aspects reg
Page 118 and 119:
Autologous BMT/PBSCT in BCR-ABL-pos
Page 120 and 121:
86 Chapter 2: ALL ABMT/PBSCT in CR2
Page 122 and 123:
88 Chapter 2: ALL Induction I Induc
Page 124 and 125:
90 Chapter 2: ALL CONCLUSIONS Molec
Page 126 and 127:
92 Chapter 2: ALL Adult Philadelphi
Page 128 and 129:
94 Chapter 2: ALL BMT. Transplantat
Page 130 and 131:
96 Chapter 2: ALL Table 1. Summary
Page 132 and 133:
98 Chapter 2: ALL 5:01 2.5:1 1.25:1
Page 134 and 135:
100 Chapter 2: ALL 11. Passweg JR,
Page 137 and 138:
Donor Lymphocyte Infusions Produce
Page 139 and 140:
Carella et al. later, and the other
Page 141 and 142:
Carella et al. Evaluation of chimer
Page 143 and 144:
Carella et al. erythropoietin follo
Page 145 and 146:
Autografring for Chronic Myeloid Le
Page 147 and 148:
Preclinical Evaluation of an Inhibi
Page 149 and 150:
Hehlmann et al. 115 idarubicin, Ara
Page 151 and 152:
BMT Hehimann et ai. 117 Diagnosis /
Page 153 and 154:
Hehlmann et al. 119 Table 4. Correl
Page 155 and 156:
Allocation: suitable for transplant
Page 157 and 158:
Hehlmann et al. 123 2. The Italian
Page 159 and 160:
Br J Haematol 23:283-288,1972. Hehl
Page 161 and 162:
Hehlmann et al. 127 JA, Dexter TM,
Page 163 and 164:
Carlo-Stella et al. 129 INTRODUCTIO
Page 165 and 166:
Carlo-Stella et al. 131 DNA fragmen
Page 167 and 168:
Carlo-Stella et al. 133 particularl
Page 169 and 170:
Carlo-Stella et al. 135 10. De Fabr
Page 171:
CHAPTER 4 LYMPHOMA
Page 174 and 175:
Late Non-Relapse Mortality After Au
Page 176 and 177:
142 Chapter 4: Lymphoma Table 2. Tr
Page 178 and 179:
144 Chapter 4: Lymphoma 1.0 1 0.4 J
Page 180 and 181:
146 Chapter 4: Lymphoma after autoS
Page 182 and 183:
148 Chapter 4: Lymphoma etoposide f
Page 184 and 185:
150 Chapter 4: Lymphoma age, sex, d
Page 186 and 187:
152 Chapter 4: Lymphoma Mobilizatio
Page 188 and 189:
154 Chapter 4: Lymphoma Missing dat
Page 190 and 191:
156 Chapter 4: Lymphoma Table 3. Ef
Page 192 and 193:
158 Chapter 4: Lymphoma REFERENCES
Page 194 and 195:
160 Chapter 4: Lymphoma Blood 79:10
Page 196 and 197:
162 Chapter 4: Lymphoma Gribben et
Page 198 and 199:
164 Chapter 4: Lymphoma purging. Si
Page 200 and 201:
Local and Regional Recurrence After
Page 202 and 203:
168 Chapter 4: Lymphoma and autoSCT
Page 204 and 205:
170 Chapter 4: Lymphoma Local or lo
Page 206 and 207:
172 Chapter 4: Lymphoma %OS 100 i 8
Page 208 and 209:
174 Chapter 4: Lymphoma %os 100. 80
Page 210 and 211:
176 Chapter 4: Lymphoma A 100 % RFS
Page 212 and 213:
178 Chapter 4: Lymphoma 100 80 %OS
Page 214 and 215:
180 Chapter 4: Lymphoma vs. sensiti
Page 216 and 217:
182 Chapter 4: Lymphoma therapy wit
Page 218 and 219:
High-Dose Therapy Followed by Hemat
Page 220 and 221:
186 Chapter 4: Lymphoma autoBMT in
Page 222 and 223:
188 Chapter 4: Lymphoma diameter. R
Page 224 and 225:
190 Chapter 4: Lymphoma 3. Fisher R
Page 226 and 227:
VACOP-B Plus Autologous Bone Marrow
Page 228 and 229:
194 Chapter 4: Lymphoma sequential
Page 230 and 231:
196 Chapter 4: Lymphoma Study desig
Page 232 and 233:
198 Chapter 4: Lymphoma 100 90 80 .
Page 234 and 235:
200 Chapter 4: Lymphoma Patients we
Page 236 and 237:
202 Chapter 4: Lymphoma 19. Fisher
Page 239 and 240:
Total Therapy With Tandem Transplan
Page 241 and 242:
Immune-Based Strategies to Improve
Page 243 and 244:
Schlossman et al. (sB2M), stage I d
Page 245 and 246:
Schlossman et al. 211 cells are rem
Page 247 and 248:
Schlossman et al. 213 Cohorts of pa
Page 249 and 250:
Schlossman et al. 215 Disease-free
Page 251 and 252:
Schlossman et al. 217 taken advanta
Page 253 and 254:
Schlossman et al. Hematol 34:49-60,
Page 255 and 256:
Schlossman et al. 221 41. Giralt S,
Page 257 and 258:
Harousseau and Attal 223 were rando
Page 259 and 260:
Harousseau and Altai 225 II—III M
Page 261 and 262:
Harousseau and Attal 227 Table 1. I
Page 263 and 264:
Harousseau and Attal Table 2. IFM 9
Page 265 and 266:
Syngeneic Transplantation in Multip
Page 267 and 268:
Gahrton et al. 233 patients were ma
Page 269 and 270:
Pretreatment With Alkylating Agents
Page 271 and 272:
Table 1. Patient characteristics Nu
Page 273 and 274:
Kiel et al. Figure 1. Quantitative
Page 275 and 276:
Kiel et al. 2 4 6 8 10 12 Number of
Page 277 and 278:
3:316-323,1997. Kiel et al. 243 6.
Page 279:
CHAPTER 6 BREAST CANCER
Page 282 and 283:
248 Chapter 6: Breast Cancer cells
Page 284 and 285:
250 Chapter 6: Breast Cancer breast
Page 286 and 287:
252 Chapter 6: Breast Cancer 10 n p
Page 288 and 289:
254 Chapter 6: Breast Cancer the ex
Page 290 and 291:
Detection of Cytokeratin + Cells in
Page 292 and 293:
258 Chapter 6: Breast Cancer cytoke
Page 294 and 295:
260 Chapter 6: Breast Cancer Table
Page 296 and 297:
Page 298 and 299:
264 Chapter 6: Breast Cancer minati
Page 300 and 301:
266 Chapter 6: Breast Cancer 18 mon
Page 302 and 303:
268 Chapter 6: Breast Cancer Tumor
Page 304 and 305:
270 Chapter 6: Breast Cancer Figure
Page 306 and 307:
272 Chapter 6: Breast Cancer cultur
Page 308 and 309:
Tandem PBSC-Supported High-Dose The
Page 310 and 311:
276 Chapter 6: Breast Cancer breast
Page 312 and 313:
278 Chapter 6: Breast Cancer effica
Page 314 and 315:
280 Chapter 6: Breast Cancer BSC Ha
Page 316 and 317:
282 Chapter 6: Breast Cancer proced
Page 318 and 319:
Page 320 and 321:
286 Chapter 6: Breast Cancer In 24
Page 322 and 323:
288 Chapter 6: Breast Cancer Cancer
Page 324 and 325:
High-Dose Chemotherapy With Autolog
Page 326 and 327:
Page 328 and 329:
294 Chapter 6: Breast Cancer receiv
Page 330 and 331:
296 Chapter 6: Breast Cancer of res
Page 332 and 333:
298 Chapter 6: Breast Cancer obtain
Page 334 and 335:
300 Chapter 6: Breast Cancer high-d
Page 336 and 337:
302 Chapter 6: Breast Cancer effect
Page 338 and 339:
304 Chapter 6: Breast Cancer three
Page 340 and 341:
306 Chapter 6: Breast Cancer patien
Page 342 and 343:
308 Chapter 6: Breast Cancer separa
Page 344 and 345:
Page 346 and 347:
312 Chapter 6: Breast Cancer 1.0-1
Page 348 and 349:
314 Chapter 6: Breast Cancer c JS S
Page 350 and 351:
316 Chapter 6: Breast Cancer 2 O X
Page 352 and 353:
318 Chapter 6: Breast Cancer progre
Page 354 and 355:
320 Chapter 6: Breast Cancer C 1.0-
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
326 Chapter 6: Breast Cancer An out
Page 362 and 363:
328 Chapter 6: Breast Cancer 4. Can
Page 364 and 365:
330 Chapter 6: Breast Cancer 33. Ov
Page 366 and 367:
An Aggressive Approach to Metastati
Page 368 and 369:
334 Chapter 6: Breast Cancer CD O 1
Page 370 and 371:
336 Chapter 6: Breast Cancer 1.0
Page 372 and 373:
Sequential High Dose Chemotherapy f
Page 374 and 375:
340 Chapter 6: Breast Cancer 10. He
Page 376 and 377:
342 Chapter 6: Breast Cancer conclu
Page 378 and 379:
344 Chapter 6: Breast Cancer after
Page 380 and 381:
Page 382 and 383:
348 Chapter 6: Breast Cancer re > '
Page 384 and 385:
350 Chapter 6: Breast Cancer BM K-1
Page 386 and 387:
352 Chapter 6: Breast Cancer regime
Page 388 and 389:
354 Chapter 6: Breast Cancer 1988 1
Page 390 and 391:
356 Chapter 6: Breast Cancer Doceta
Page 392 and 393:
Page 394 and 395:
360 Chapter 6: Breast Cancer DIFFER
Page 396 and 397:
Expression of C-ErbB-2/Her-2 in Pat
Page 398 and 399:
364 Chapter 6: Breast Cancer MATERI
Page 400 and 401:
366 Chapter 6: Breast Cancer weeks.
Page 402 and 403:
368 Chapter 6: Breast Cancer (P=0.0
Page 404 and 405:
370 Chapter 6: Breast Cancer result
Page 406 and 407:
372 Chapter 6: Breast Cancer ACKNOW
Page 408 and 409:
374 Chapter 6: Breast Cancer apy in
Page 411 and 412:
High-Dose Chemotherapy and Autologo
Page 413 and 414:
Stiff, Kerger, and Bayer 379 75 mg/
Page 415 and 416:
Table 1. Clinical characteristics S
Page 417 and 418:
Survival 1.00 .80 4 .60 i .40 1 .20
Page 419 and 420:
Stiff, Kerger, and Bayer 385 patien
Page 421 and 422:
57:278-285,1995. Stiff, Kerger, and
Page 423 and 424:
Abonour et al. 389 INTRODUCTION Wit
Page 425 and 426:
Abonour et al. 391 A more recent ex
Page 427 and 428:
Abonour et al. 393 DFS by Prognosti
Page 429 and 430:
Abonour et al. 395 6. Motzer RJ, Co
Page 431 and 432:
Leyvraz et al. 397 Table 1. Results
Page 433 and 434:
Table 3. ICE toxicity (172 cycles)
Page 435 and 436:
Leyvraz et al. 401 intensive treatm
Page 437 and 438:
Elias et al. (CAV) and with etoposi
Page 439 and 440:
Elias et al. tumor, or in the case
Page 441 and 442:
Elias et al. selection of patients
Page 443 and 444:
Elias et al. partial purge of the a
Page 445 and 446:
ProcASCO 16:456a, 1997. Elias et al
Page 447 and 448:
Elias et al. late dose intensificat
Page 449 and 450:
Elias et al. G, McCauley M, Gaynes
Page 451 and 452:
Transplantation With PBSC, Manipula
Page 453 and 454:
Takaue et al. 419 transfusion (day
Page 455 and 456:
Takaue et al. All tation, this proc
Page 457 and 458:
Rodenhuis et al. 423 INTRODUCTION H
Page 459 and 460:
mg/m 2 Rodenhuis et al. 425 in pati
Page 461 and 462:
Rodenhuis et al. All interest. One
Page 463 and 464:
Rodenhuis et al. 429 Figure 2. Prog
Page 465 and 466:
c 1000 -I Rodenhuis et al. 0 4 8 Ti
Page 467 and 468:
Rodenhuis et al. 433 First, a respo
Page 469 and 470:
Epirubicin Plus G-CSF-Elicited Peri
Page 471 and 472:
Carlo-Stella et al. 437 tissues fro
Page 473 and 474:
Carlo-Stella et al. 439 Epi 1 20 mg
Page 475 and 476:
A 140 -i 120- _i 100- CO 80 - O 60
Page 477 and 478:
Carlo-Stella et al. immediately evi
Page 479 and 480:
lastomas. Anticancer Drugs 8:174-18
Page 481:
CHAPTER 8 AUTOIMMUNE DISEASE
Page 484 and 485:
450 Chapter 8: Autoimmune Disease u
Page 486 and 487:
Autologous Blood Stem Cell Therapy
Page 488 and 489:
454 Chapter 8: Autoimmune Disease T
Page 490 and 491:
456 Chapter 8: Autoimmune Disease w
Page 492 and 493:
Page 494 and 495:
Page 496 and 497:
Page 498 and 499:
Hematopoietic Stem Ceil Transplanta
Page 500 and 501:
466 Chapter 8: Autoimmune Disease i
Page 502 and 503:
468 Chapter 8: Autoimmune Disease s
Page 504 and 505:
470 Chapter 8: Autoimmune Disease 1
Page 506 and 507:
Autologous Stem Cell Therapy in Aut
Page 508 and 509:
Page 510 and 511:
Autologous Hematopoietic Stem Cell
Page 512 and 513:
Page 514 and 515:
480 Chapter 8: Autoimmune Disease r
Page 517 and 518:
Presence in Pretransplant Marrow of
Page 519 and 520:
Table 1. Study 1 patient characteri
Page 521 and 522:
Radford et al. 487 1 2 3 4 5 6 7 8
Page 523 and 524:
Radford et al. 489 transplantation,
Page 525 and 526:
Importance of Marrow Doses and Mode
Page 527 and 528:
Gorin TC 199 medium and finally fro
Page 529 and 530:
Gorin 495 ABMT IN AL Engraftment on
Page 531 and 532:
Gorin Table 5. Engraftment accordin
Page 533 and 534:
Gorin 499 ABMT IN AL Outcome in rel
Page 535 and 536:
OS% Gorin 501 1 1 1 • • 0 i 1 1
Page 537 and 538:
Gorin 503 S, Carlier P, Giordano D,
Page 539 and 540:
15:769-775, 1995. Gorin 505 35. Dou
Page 541 and 542:
Long-Term Observations Following He
Page 543:
Deeg et al 509 Table 2. Secondary m
Page 547 and 548:
Gene Marking to Assess Tumor Contam
Page 549 and 550:
Heslop et al. 515 clonogenic assays
Page 551 and 552:
Heslop et al. 517 Disease Free Surv
Page 553 and 554:
Heslop et al. 519 providing the cli
Page 555 and 556:
Enrichment of Tumor Cells From Auto
Page 557 and 558:
Ross et al. post-TEC fraction was c
Page 559 and 560:
Ross et al. 525 Table 2. Results of
Page 561 and 562:
Ross et al. that the capture antibo
Page 563 and 564:
Combining Positive/Negative Selecti
Page 565 and 566:
Mapara et al. 531 products of patie
Page 567 and 568:
Mapara et al. 533 Hematopoietic col
Page 569 and 570:
Mapara et al. 535 A i m : P u r g i
Page 571 and 572:
Mapara et al. 537 A |_ «••«
Page 573 and 574:
Mapara et al. 539 11. Shpall EJ, Le
Page 575 and 576:
Tumor Purging Technologies: More Qu
Page 577 and 578:
Gee 543 argued that these two patie
Page 579 and 580:
Gee 545 immunomagnetic particles to
Page 581 and 582:
Gee 547 POSITIVE OR NEGATIVE? Given
Page 583 and 584:
Gee 549 autologous transplants of c
Page 585 and 586:
Behavior of Hematopoietic Stem Cell
Page 587 and 588:
Henschler et al. 553 MATERIALS AND
Page 589 and 590:
Table 1. Engraftment of human CD34
Page 591 and 592:
Henschler et al. 557 an increase of
Page 593 and 594:
Henschler et dl. 559 plantation for
Page 595 and 596:
CD34 Selection and Autografting in
Page 597 and 598:
Table 1. Patient characteristics, n
Page 599 and 600:
Voso et al. 565 The side scatter (S
Page 601 and 602:
Table 3. Immunophenotype of CD34 +
Page 603 and 604:
Voso et al. 569 neuroblastoma and a
Page 605 and 606:
Voso et al. 571 transplantation for
Page 607 and 608:
Neutrophils Days 100 Days to >500
Page 609 and 610:
Dicke et al. 575 CD34 Labeling Samp
Page 611 and 612:
Dicke et al. 577 Table 3. Platelet
Page 613 and 614:
Dicke et al. 579 3. Ager S, Scott M
Page 615 and 616:
Janssen et al. 581 PBSC products. H
Page 617 and 618:
Janssen et al. Table 1. Characteris
Page 619 and 620:
5X10 5 Janssen et ai. 585 In brief,
Page 621 and 622:
Janssen et al. CD34+ CELLS INFUSED/
Page 623 and 624:
1.0 0.9 0.8 0.7 0.6 0.5 0.4 0.3 0.2
Page 625 and 626:
Janssen et al. RELAPSE FREE SURVIVA
Page 627 and 628:
CD34 + Janssen et al. cells and CFU
Page 629 and 630:
Janssen et al. 595 8. Dercksen MW,
Page 631 and 632:
Janssen et al. 597 32. Sosman JA, S
Page 633:
CHAPTER 11 MINITRANSPLANTS
Page 636 and 637:
602 Chapter 11: Minitransplants to
Page 638 and 639:
604 Chapter 11: Minitransplants Tab
Page 640 and 641:
Page 642 and 643:
608 Chapter 11: Minitransplants tra
Page 644 and 645:
610 Chapter 11: Minitransplants 14.
Page 646 and 647:
Allogeneic Progenitor Cell Transpla
Page 648 and 649:
614 Chapter 11: Minitransplants 100
Page 650 and 651:
Page 652 and 653:
618 Chapter 11: Minitransplants all
Page 655 and 656:
Transduction of Primitive Hematopoi
Page 657 and 658:
Jordan et al. shown that such a hyb
Page 659 and 660:
Table 1. Initial findings with seve
Page 661 and 662:
Jordan et al. In preclinical studie
Page 663 and 664:
Molecular Intervention in Myeloma A
Page 665:
CHAPTER 13 IMMUNOTHERAPY
Page 668 and 669:
Immune-toxins Containing Pokeweed A
Page 670 and 671:
636 Chapter 13: Immunotherapy tumor
Page 672 and 673:
638 Chapter 13: Immunotherapy unide
Page 674 and 675:
640 Chapter 13: Immunotherapy lymph
Page 676 and 677:
642 Chapter 13: Immunotherapy accom
Page 678 and 679:
644 Chapter 13: Immunotherapy Figur
Page 680 and 681:
646 Chapter 13: Immunotherapy CD80P
Page 682 and 683:
648 Chapter 13: Immunotherapy are o
Page 684 and 685:
650 Chapter 13: Immunotherapy 23. F
Page 686 and 687:
652 Chapter 13: Immunotherapy 57. T
Page 688 and 689:
Adjuvant Immunotherapy in Conjuncti
Page 690 and 691:
656 Chapter 13: Immunotherapy mg/m
Page 692 and 693:
658 Chapter 13: Immunotherapy NHL a
Page 694 and 695:
660 Chapter 13: Immunotherapy tion
Page 696 and 697:
662 Chapter 13: Immunotherapy Table
Page 698 and 699:
664 Chapter 13: Immunotherapy leuke
Page 701 and 702:
The Brambell Receptor (FcRB) and th
Page 703 and 704:
5h P 11- V Junghans 669 o I 1 1 1 1
Page 705 and 706:
Junghans 10 20 30 40 IgG Concentrat
Page 707 and 708:
1001- 90 80 E 70 § 60 K g 50 u z 8
Page 709 and 710:
Junghans 675 Time, days Figure 8. B
Page 711 and 712:
Junghans 677 The site on Fc for int
Page 713 and 714:
Junghans 679 1969. 20. Junghans RP,
Page 715 and 716:
Approaches to the Radiation Dosimet
Page 717 and 718:
Fisher 683 bution to marrow dose is
Page 719 and 720:
Fisher 685 organ k per unit cumulat
Page 721 and 722:
Fisher 687 acetabulum. The curve is
Page 723 and 724:
Fisher 689 Table 2. Correlations be
Page 725 and 726:
Fisher 8. Sgouros G: Bone marrow do
Page 727:
Radioimmunotherapy for Malignant Ly
Page 731 and 732:
Induction of Graft-vs.-Malignancy a
Page 733 and 734:
Champlin, Khouri, and Giralt 699 is
Page 735 and 736:
Champlin, Khouri, and Girat 701 and
Page 737 and 738:
Champlin, Khouri, and Giralt 703 ti
Page 739 and 740:
Champlin, Khouri, and Giralt 705 A
Page 741 and 742:
Champlin, Khouri, and Giralt 707 E,
Page 743 and 744:
Whimbey 709 INTRODUCTION Infectious
Page 745 and 746:
Whimbey 711 CRVs are a common cause
Page 747 and 748:
Whimbey 713 antibody titers to RSV
Page 749 and 750:
Whimbey 715 toxic, less costly, and
Page 751 and 752:
Asymmetric Division as Measurable P
Page 753:
Neuropoiesis Peter Quesenberry, Car
Page 757 and 758:
Summary: Leukemia John Barrett Bone
Page 759 and 760:
Barrett New directions A role for i
Page 761 and 762:
Autologous Blood and Marrow Transpl
Page 763 and 764:
across page) Elfenbein 729 Examples
Page 765 and 766:
Elfenbein 731 Examples Contributors
Page 767 and 768:
Table 3. Types of clinical trials i
Page 769 and 770:
Strategies in Autologous Bone Marro
Page 771 and 772:
Summary: Lymphoma Armand Keating On
Page 773 and 774:
Rafat Abonour Indiana Univ. Cancer
Page 775 and 776:
H-Joachim Deeg Fred Hutchinson Canc
Page 777 and 778:
Richard P. Junghans Division of Hem
Page 779 and 780:
Peter J. Quesenberry Univ. of Massa
Page 781 and 782:
Linda T. Vahdat Columbia Presbyteri
Page 783 and 784:
DiStefano, Alfred 332 Dodero, Anna
Page 785 and 786:
Author Index 751 Ohno-Jones, S. 113
Page 787 and 788:
KEY WORD INDEX 4-HC 1 Brambell rece
Page 789:
Refractory anemia with excess blast
show all

autologous blood and marrow transplantation - Blog Science ...

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?